Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06599216
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-11
Brief Title:
Adebrelimab Combined with Dalpiciclib and Standard Endocrine Therapy for HR HER2- Breast Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Adebrelimab Combined with Dalpicicliband Standard Endocrine Therapy for HR HER 2-breast CancerA Single-centerOpen-labelSingle-arm Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to explore the efficacy and safety of PD-L1 inhibitor Adebrelimab combined with the CDK46 inhibitor Dalpcicilib and standard endocrine therapy given as neoadjuvant treatment in stages II-III hormone receptor-positive HR human epidermal growth factor receptor 2-negative HER2- breast cancer
Detailed Description:
This single-center open-label single-arm clinical trial aims to evaluate the efficacy and safety of the neoadjuvant treatment with the PD-L1 inhibitor Adebrelimab in combination with the CDK46 inhibitor Dalpicicilib in combination with standard endocrine therapy for stages II-III hormone receptor-positive HR human epidermal growth factor receptor 2-negative HER2- breast cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None